ONCOLOGIST
Scope & Guideline
Advancing cancer research for a brighter tomorrow.
Introduction
Aims and Scopes
- Clinical Trials and Treatment Innovations:
The journal focuses on the latest clinical trials and novel treatment strategies across various cancer types, emphasizing personalized medicine and immunotherapy. - Real-World Evidence and Outcomes:
It includes studies that analyze real-world data to evaluate treatment outcomes, adherence, and healthcare resource utilization, providing insights into how therapies perform outside controlled clinical settings. - Molecular and Genomic Insights:
Research on the molecular and genetic characterization of tumors is a core theme, with an emphasis on identifying biomarkers that can predict treatment responses and outcomes. - Patient-Centered Care:
The journal highlights the importance of patient-reported outcomes, quality of life assessments, and the psychosocial aspects of cancer treatment, ensuring that patient perspectives are integrated into research. - Health Equity and Access to Care:
There is a growing emphasis on studies investigating disparities in cancer care, including access to treatments and outcomes among different demographic groups. - Innovative Methodologies:
The journal is open to novel research methodologies, including the use of artificial intelligence and machine learning in oncology, as well as advanced imaging and diagnostic techniques.
Trending and Emerging
- Immunotherapy and Combination Treatments:
There is a significant increase in publications centered around immunotherapy, particularly studies exploring combination therapies that enhance efficacy and manage resistance. - Liquid Biopsies and Non-Invasive Diagnostics:
Research focusing on liquid biopsies for early detection and monitoring of treatment responses is gaining traction, highlighting the shift towards less invasive diagnostic methods. - Artificial Intelligence in Oncology:
The application of AI and machine learning in predicting treatment outcomes and personalizing therapy is emerging as a vital area of research, reflecting technological advancements. - Patient-Centric Approaches:
An increased emphasis on patient-reported outcomes, survivorship issues, and quality of life assessments indicates a trend towards more holistic cancer care. - Health Disparities and Equity Research:
Research addressing health disparities and equity in cancer care is on the rise, emphasizing the need to address inequities in treatment access and outcomes across diverse populations. - Integrative Oncology:
The exploration of complementary therapies and integrative approaches alongside conventional treatments is becoming a more prominent theme, reflecting patient interest in holistic care.
Declining or Waning
- Traditional Chemotherapy Studies:
There appears to be a waning interest in studies focused solely on traditional chemotherapy regimens without the integration of novel agents or combination therapies, as the field moves towards more personalized and targeted approaches. - Single-Agent Studies:
Research solely examining the efficacy of single-agent therapies is becoming less prevalent, with a shift towards combination therapies that may enhance effectiveness and reduce resistance. - Basic Science without Clinical Application:
There is a noticeable reduction in papers that focus exclusively on basic science findings without a clear translational application to clinical settings, as the journal aims to bridge laboratory research and patient care. - Outdated Treatment Protocols:
Studies examining older treatment protocols, especially those that do not incorporate newer guidelines or advancements in cancer care, are becoming less common as the field rapidly evolves. - General Cancer Awareness Campaigns:
While important, general awareness programs are being overshadowed by more focused research on specific interventions, tailored treatments, and health disparities.
Similar Journals
LANCET ONCOLOGY
Discovering innovative solutions for complex oncology challenges.The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.
Translational Oncology
Transforming Cancer Insights into Clinical SolutionsTranslational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.
Future Oncology
Fostering collaboration for a cancer-free future.Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.
Oncology Reviews
Exploring Innovations in Cancer Treatment and ResearchOncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.
Asia-Pacific Journal of Clinical Oncology
Elevating clinical practices with cutting-edge research.Asia-Pacific Journal of Clinical Oncology is an essential publication within the field of medical oncology, dedicated to advancing the understanding and treatment of cancer through rigorous research and innovative clinical practices. Published by WILEY, this journal has established itself as a significant resource for researchers, healthcare professionals, and students interested in the latest findings across the Asia-Pacific region and beyond. With a respectable impact factor and categorized within the Q2 and Q3 quartiles of Medicine (miscellaneous) and Oncology respectively, the journal aims to disseminate knowledge on diverse aspects of clinical oncology, promoting the improvement of patient care and treatment outcomes. The Asia-Pacific Journal of Clinical Oncology, operating from the United Kingdom, invites contributions that highlight significant findings and advancements in oncology, making it a crucial platform for collaboration and knowledge sharing in this vital field of medicine.
Clinical Lung Cancer
Exploring breakthroughs in lung cancer therapy and research.Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.
JOURNAL OF CLINICAL ONCOLOGY
Advancing oncology research for a healthier tomorrow.Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.
Journal of the National Comprehensive Cancer Network
Uniting Knowledge: A Premier Resource for Oncology Research and PracticeThe Journal of the National Comprehensive Cancer Network (ISSN: 1540-1405, E-ISSN: 1540-1413) is a premier publication in the field of oncology, established by HARBORSIDE PRESS and running since 2003. This highly respected journal holds a remarkable Q1 ranking in both Medicine (Miscellaneous) and Oncology categories, showcasing its significant influence and contribution to cancer research, with a Scopus ranking placing it within the top 5% of its field (Rank #20 out of 404). Aimed at a diverse audience including researchers, clinicians, and students, the journal publishes a wide range of articles that explore cutting-edge findings, clinical practices, and evidence-based guidelines in cancer care. With its commitment to advancing the understanding and treatment of cancer, it serves as a vital resource for professionals dedicated to improving patient outcomes. Although it does not currently offer open access, its impactful content continues to be a cornerstone for anyone involved in oncology research and practice.
Clinical Genitourinary Cancer
Pioneering discoveries for improved patient outcomes.Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.
International Journal of Clinical Oncology
Fostering Excellence in Hematology and OncologyInternational Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.